Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)—chronic myelogenous leukemia, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)—as well as chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia/hypereosinophilic syndrome (CEL/HES) and ‘CMPD, unclassifiable’. In the upcoming 4th edition of the WHO document, due out in 2008, the term ‘CMPDs’ is replaced by ‘myeloproliferative neoplasms (MPNs)’, and the MPN category now includes mast cell disease (MCD), in addition to the other subcategories mentioned above. At the same time, however, myeloid neoplasms with molecularly characterized clonal eosinophilia, previously classified under CEL/HES, are now removed from the MPN section and assembled into a new category of their own. The WHO diagnostic criteria for both the classic BCR–ABL-negative MPDs (that is PV, ET and PMF) and CEL/HES have also been revised, in the 2008 edition, by incorporating new information on their molecular pathogenesis. The current review highlights these changes and also provides diagnostic algorithms that are tailored to routine clinical practice.

[1]  K. Nishii,et al.  Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature , 2007, Leukemia.

[2]  J. Hoyer,et al.  The JAK2 V617F Mutation is Absent in Patients with Erythrocytosis Due to High Oxygen Affinity Hemoglobin Variants , 2006, Hemoglobin.

[3]  D. Steensma,et al.  JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained , 2006, Leukemia.

[4]  J. Marsden,et al.  Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia , 2002, British journal of haematology.

[5]  F. Locatelli,et al.  JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia , 2007, Leukemia.

[6]  W. Dameshek.  Editorial: Some Speculations on the Myeloproliferative Syndromes , 1951 .

[7]  M. Calasanz,et al.  JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients , 2006, Leukemia.

[8]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[9]  P. O'Connell,et al.  Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. , 1994, The New England journal of medicine.

[10]  I. Lorand-Metze,et al.  Histological and cytological heterogeneity of bone marrow in Philadelphia‐positive chronic myelogenous leukaemia at diagnosis , 1987, British journal of haematology.

[11]  B. Quesnel,et al.  High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis , 2006, Leukemia.

[12]  A. Tefferi,et al.  Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. , 2007, Mayo Clinic proceedings.

[13]  A. Tefferi,et al.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. , 2004, Blood.

[14]  E. Lippert,et al.  Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617F , 2007, Leukemia.

[15]  A. Tefferi,et al.  Systemic mastocytosis: current concepts and treatment advances. , 2004, Current hematology reports.

[16]  A. Tefferi,et al.  JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder , 2007, Journal of thrombosis and haemostasis : JTH.

[17]  P. Möller,et al.  Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma , 2006, Leukemia.

[18]  Z. Berneman,et al.  Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia , 2004, Annals of Hematology.

[19]  D. Gilliland,et al.  Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia , 2005, British journal of haematology.

[20]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[21]  D. Gilliland,et al.  Oncogenes in Myeloproliferative Disorders , 2007, Cell cycle.

[22]  T. Barbui,et al.  The haematocrit and platelet target in polycythemia vera , 2007, British journal of haematology.

[23]  M. Bernard,et al.  Inapparent polycythemia vera: an unrecognized diagnosis. , 1997, The American journal of medicine.

[24]  B. Bain,et al.  Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. , 2007, Immunology and allergy clinics of North America.

[25]  A. Tefferi,et al.  Red cell mass and plasma volume measurements in polycythemia: , 2005, Cancer.

[26]  M. Raffeld,et al.  Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. , 2004, The Journal of molecular diagnostics : JMD.

[27]  J. Thiele,et al.  Hematopathologic findings in chronic idiopathic myelofibrosis. , 2005, Seminars in oncology.

[28]  A. Reiter,et al.  Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages , 1998, British journal of haematology.

[29]  S. Verstovsek,et al.  JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? , 2006, Leukemia.

[30]  J. Vardiman,et al.  Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. , 2006, Best practice & research. Clinical haematology.

[31]  A. Tefferi,et al.  WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature , 2005, Leukemia.

[32]  L. Scott,et al.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. , 2000, Experimental hematology.

[33]  V. Diehl,et al.  The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias. , 2001, Haematologica.

[34]  V. Fairbanks,et al.  Polycythemia Vera: The Packed Cell Volume and The Curious Logic of The Red Cell Mass. , 1999, Hematology.

[35]  T. Pearson.  Apparent polycythaemia. , 1991, Blood reviews.

[36]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[37]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[38]  P. Fialkow.  Cell lineages in hematopoietic neoplasia studied with glucose‐6‐phosphate dehydrogenase cell markers , 1982, Journal of cellular physiology. Supplement.

[39]  A. Schmitt-Graeff,et al.  Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. , 2002, Haematologica.

[40]  P. Lipsky,et al.  Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. , 2002, Blood.

[41]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[42]  J. Adamson,et al.  Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.

[43]  T. Gilewski,et al.  Biologic response modifiers in non-Hodgkin's lymphomas. , 1990, Seminars in oncology.

[44]  L. Wasserman.  The treatment of polycythemia. A panel discussion. , 1968, Blood.

[45]  R. McClure,et al.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.

[46]  François Girodon,et al.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.

[47]  T. Hudson,et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome , 1998, Nature Genetics.

[48]  H. Gralnick,et al.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.

[49]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[50]  Wasserman Lr.  The treatment of polycythemia. A panel discussion. , 1968 .

[51]  E. Ma,et al.  JAK2 V617F due to a novel TG → CT mutation at nucleotides 1848–1849: diagnostic implication , 2007, Leukemia.

[52]  A. Tzankov,et al.  The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis , 2006, Leukemia.

[53]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[54]  M. Barceló,et al.  Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. , 1997, Haematologica.

[55]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[56]  E. Estey,et al.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.

[57]  P. Guglielmelli,et al.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.

[58]  M. Loh,et al.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.

[59]  H. Müller-Hermelink,et al.  Detecting the JAK2 V617F mutation in fresh and ‘historic’ blood and bone marrow , 2007, Leukemia.

[60]  M. Loh,et al.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. , 2005, Blood.

[61]  M. Loh,et al.  Inherited predispositions and hyperactive Ras in myeloid leukemogenesis , 2006, Pediatric blood & cancer.

[62]  A. Tefferi,et al.  Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.

[63]  J. Maciejewski,et al.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. , 2006, Blood.

[64]  P. Chiusolo,et al.  Screening of JAK2 V617F mutation in multiple myeloma , 2006, Leukemia.

[65]  D. Steensma,et al.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.

[66]  G. Mufti,et al.  The JAK2 V617F mutation is rare in RARS but common in RARS-T , 2006, Leukemia.

[67]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[68]  D. Gilliland,et al.  The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. , 2005, Mayo Clinic proceedings.

[69]  P. Fialkow,et al.  Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.

[70]  D. Koh,et al.  Clonality of isolated eosinophils in the hypereosinophilic syndrome. , 1999, Blood.

[71]  S. H. Lee,et al.  The JAK2 V617F mutation in de novo acute myelogenous leukemias , 2006, Oncogene.

[72]  A. Tefferi,et al.  JAK2 mutations in myeloproliferative disorders. , 2005, The New England journal of medicine.

[73]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[74]  A. Tefferi,et al.  JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder , 2007, Leukemia.

[75]  D. Gilliland,et al.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.

[76]  A. Tefferi,et al.  Eosinophilia: secondary, clonal and idiopathic , 2006, British journal of haematology.

[77]  M. Wadleigh,et al.  JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance , 2005, British journal of haematology.

[78]  F. Girodon,et al.  Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. , 2004, Haematologica.

[79]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[80]  J. Laszlo,et al.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.

[81]  松山 智洋.  What's going on 造血器腫瘍 A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. N Engl J Med. 2005; 352: 1779-90. PMID:15858187.--慢性骨髄増殖性疾患においてJAK2遺伝子の変異が高頻度にみられることを示した論文 , 2005 .

[82]  E. Lippert,et al.  Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. , 2006, Blood.

[83]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[84]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[85]  P. Nowell,et al.  Chromosome studies on normal and leukemic human leukocytes. , 1960, Journal of the National Cancer Institute.

[86]  T. Nutman,et al.  Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome , 2006, British journal of haematology.

[87]  P. Heimann,et al.  The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors , 2006, Leukemia.

[88]  A. Tefferi,et al.  Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera , 2007, Leukemia.

[89]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[90]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[91]  N. Berlin.  Diagnosis and classification of the polycythemias. , 1975, Seminars in hematology.

[92]  A. Aventín,et al.  Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. , 2006, Haematologica.

[93]  E. Torlakovic,et al.  Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia , 1998, Leukemia.

[94]  W. Vainchenker,et al.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.

[95]  B. Woda,et al.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features , 2006, Leukemia.

[96]  A. Hall,et al.  The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia , 2005, British journal of haematology.

[97]  J. Cools,et al.  Chronic myeloproliferative disorders: a tyrosine kinase tale , 2006, Leukemia.

[98]  J. Bennett.  A comparative review of classification systems in myelodysplastic syndromes (MDS). , 2005, Seminars in oncology.

[99]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[100]  S. Gartler,et al.  Clonal origin of chronic myelocytic leukemia in man. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[101]  L. Kanz,et al.  Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera , 2006, Leukemia.

[102]  S. Fröhling,et al.  Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. , 2006, Blood.

[103]  P. Martiat,et al.  Molecular analysis of Philadelphia positive essential thrombocythemia. , 1989, Leukemia.

[104]  M. Ruiz,et al.  A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. , 2005, Leukemia research.

[105]  V. Fairbanks.  Myeloproliferative Disease: Polycythemia Vera: The Packed Cell Volume and The Curious Logic of The Red Cell Mass. , 2000, Hematology.

[106]  G. Faguet,et al.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.

[107]  A. Tefferi,et al.  The diagnostic interface between histology and molecular tests in myeloproliferative disorders , 2007, Current opinion in hematology.

[108]  A. Dispenzieri,et al.  FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. , 2004, Haematologica.

[109]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[110]  H. Schaefer,et al.  Evidence of clonality in chronic neutrophilic leukaemia , 2003, Journal of clinical pathology.

[111]  R. Levine,et al.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. , 2005, Blood.

[112]  A. Tefferi,et al.  Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera , 2007, Leukemia.

[113]  P. Lev,et al.  JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status , 2006, European journal of haematology.

[114]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[115]  A. Tefferi.  JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. , 2007, The New England journal of medicine.

[116]  S. Fujita,et al.  Neoplastic involvement of granulocytic lineage, not granulocytic‐monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia case report , 1998, American journal of hematology.